Homology Medicines/FIXX

$0.92

2.83%
-
1D1W1MYTD1YMAX

About Homology Medicines

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with phenylketonuria (PKU); HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome; and HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with PKU. Its lead GTx-mAb gene therapy candidate, HMI-104, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Its platform is designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to precisely and efficiently deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality and gene therapy platform.

Ticker

FIXX

Sector

Healthcare

Trading on

NASDAQ

Industry

Retail (Drugs)

CEO

Arthur Tzianabos

Employees

92

Headquarters

Bedford, United States

FIXX Metrics

BasicAdvanced
$50.11M
Market cap
-
P/E ratio
-$2.27
EPS
-0.13
Beta
-
Dividend rate

What the Analysts think about FIXX

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 1 analysts.
63.04% upside
High $1.50
Low $1.50
$0.92
Current price
$1.50
Average price target

FIXX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-100%
Net income
$-32.9M
-6%
Profit margin
0%
-100%

FIXX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 35.71%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.60
-$0.50
-$0.61
-$0.57
-
Expected
-$0.50
-$0.53
-$0.48
-$0.42
-$0.30
Surprise
19.11%
-5.66%
28.42%
35.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Homology Medicines stock

Buy or sell Homology Medicines stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing